AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
AbCellera (Nasdaq: ABCL) presented new data on its T-cell engager (TCE) platform at the SITC 39th Annual Meeting in Houston. The presentation showcases strategies for TCE development, including CD3-binding antibodies for enhanced tumor-cell killing and optimal cytokine release. The company highlighted molecules designed to improve efficacy in solid tumor treatment through T-cell activation and proliferation via CD28 and 4-1BB costimulation. The data includes preclinical characterization of TCEs targeting B7-H4 and PSMA solid tumor targets, demonstrating distinctive tumor-cell killing and cytokine release profiles compared to clinical benchmarks.
AbCellera (Nasdaq: ABCL) ha presentato nuovi dati sulla sua piattaforma di T-cell engager (TCE) durante la 39ª Riunione Annuale SITC a Houston. La presentazione illustra strategie per lo sviluppo di TCE, inclusi anticorpi che si legano al CD3 per migliorare l'uccisione delle cellule tumorali e il rilascio ottimale di citochine. L'azienda ha evidenziato molecole progettate per migliorare l'efficacia nel trattamento dei tumori solidi grazie all'attivazione e alla proliferazione delle cellule T tramite la costimolazione di CD28 e 4-1BB. I dati includono la caratterizzazione preclinica dei TCE che mirano a bersagli tumorali solidi B7-H4 e PSMA, dimostrando profili distintivi di uccisione delle cellule tumorali e rilascio di citochine rispetto ai benchmark clinici.
AbCellera (Nasdaq: ABCL) presentó nuevos datos sobre su plataforma de T-cell engager (TCE) en la 39ª Reunión Anual de SITC en Houston. La presentación muestra estrategias para el desarrollo de TCE, incluyendo anticuerpos que se unen a CD3 para mejorar la eliminación de células tumorales y el liberación óptima de citoquinas. La empresa destacó moléculas diseñadas para mejorar la eficacia en el tratamiento de tumores sólidos mediante la activación y proliferación de células T a través de la costimulación de CD28 y 4-1BB. Los datos incluyen la caracterización preclínica de TCE dirigidos a los objetivos tumorales sólidos B7-H4 y PSMA, demostrando perfiles distintivos de eliminación de células tumorales y liberación de citoquinas en comparación con los puntos de referencia clínicos.
AbCellera (Nasdaq: ABCL)는 휴스턴에서 열린 SITC 제39회 연례 회의에서 T세포 유인체 (TCE) 플랫폼에 대한 새로운 데이터를 발표했습니다. 이 발표는 TCE 개발을 위한 전략을 보여주며, 여기에는 종양 세포 사멸을 증가시키고 최적의 사이토카인 방출을 위한 CD3 결합 항체가 포함됩니다. 이 회사는 CD28 및 4-1BB 공동 자극을 통해 T 세포의 활성화 및 증식을 통해 고형 종양 치료의 효능을 개선하기 위해 설계된 분자를 강조했습니다. 데이터에는 B7-H4 및 PSMA 고형 종양 목표를 겨냥한 TCE의 전임상 특성이 포함되어 있으며, 임상 기준과 비교했을 때 뚜렷한 종양 세포 살해 및 사이토카인 방출 프로필을 보여줍니다.
AbCellera (Nasdaq: ABCL) a présenté de nouvelles données sur sa plateforme d'engageur de cellules T (TCE) lors de la 39e Réunion Annuelle de la SITC à Houston. La présentation met en avant des stratégies pour le développement de TCE, y compris des anticorps se liant à CD3 pour améliorer l'élimination des cellules tumorales et la libération optimale de cytokines. L'entreprise a mis en lumière des molécules conçues pour améliorer l'efficacité dans le traitement des tumeurs solides grâce à l'activation et à la prolifération des cellules T via la costimulation de CD28 et 4-1BB. Les données incluent la caractérisation préclinique des TCE ciblant les tumeurs solides B7-H4 et PSMA, montrant des profils distinctifs d'élimination des cellules tumorales et de libération de cytokines par rapport aux références cliniques.
AbCellera (Nasdaq: ABCL) hat auf dem 39. Jahrestreffen der SITC in Houston neue Daten zu seiner T-Zell-Engager (TCE)-Plattform präsentiert. Die Präsentation zeigt Strategien für die Entwicklung von TCE, einschließlich CD3-bindenden Antikörpern zur Verbesserung der Tumorzelltötung und optimaler Zytokinfreisetzung. Das Unternehmen hob Moleküle hervor, die entworfen wurden, um die Wirksamkeit bei der Behandlung solider Tumoren durch T-Zell-Aktivierung und -Proliferation mittels CD28- und 4-1BB-Kostimulation zu verbessern. Die Daten umfassen die präklinische Charakterisierung von TCEs, die auf solide Tumormarker B7-H4 und PSMA abzielen, und zeigen spezifische Tumorzelltötungs- und Zytokinfreisetzungsprofile im Vergleich zu klinischen Benchmarks.
- Demonstrated differentiated tumor-cell killing profiles compared to clinical benchmarks
- Advanced development in multiple solid tumor targets (B7-H4 and PSMA)
- Platform shows potential for enhanced therapeutic efficacy through T-cell activation
- Programs still in preclinical stage, indicating long path to commercialization
AbCellera’s presentation, which is available for viewing here, describes:
Strategies to address key challenges in TCE development:
- CD3-binding antibodies to widen the therapeutic window by generating TCEs with potent tumor-cell killing and optimal cytokine release
- Molecules to enhance efficacy for solid tumor indications by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB
Application of the platform to two of AbCellera’s TCE programs:
- Preclinical characterization of TCEs against solid tumor targets B7-H4 and PSMA show tumor-cell killing and cytokine release profiles that are differentiated from clinical benchmarks
About AbCellera’s T-Cell Engager Platform
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, the development of T-cell engagers has been limited due to challenges with efficacy and safety. To address these challenges, AbCellera developed a T-cell engager platform that includes novel CD3-binding antibodies to expand the therapeutic window for this modality, costimulatory building blocks to enhance efficacy for difficult-to-treat cancers, and discovery capabilities to broaden the range of T-cell engagers to complex tumor targets. AbCellera is leveraging its platform to unlock the full potential of this modality and bring potential new cancer medicines to patients.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107880960/en/
Inquiries
Media: Kathleen Reid; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116
Source: AbCellera Biologics Inc.
FAQ
What tumor targets did ABCL's T-cell engager platform demonstrate efficacy against?
What are the key features of ABCL's T-cell engager platform presented at SITC 2024?
How does ABCL's TCE platform compare to clinical benchmarks?
